Kakarieka A, Braakman R, Schakel E H
Clinical Research CNS, Tropon, Köln, Federal Republic of Germany.
Acta Neurochir (Wien). 1994;129(1-2):1-5. doi: 10.1007/BF01400864.
The population analysed consisted of 268 out of 819 patients of a European nimodipine multicentre trial on severe head injury, whose first CT scan after injury showed signs of subarachnoid bleeding. The study demonstrated the importance of traumatic subarachnoid haemorrhage (tSAH) per se as a prognostic factor. The outcome of patients with tSAH is significantly worse than that of patients whose first CT does not show subarachnoid blood (noSAH). The outcome was unfavourable (dead, persistent vegetative state, severe disability) in 60% of tSAH patients compared to 30% of noSAH patients (p < 0.001). The difference in mortality was 42% vs. 14% (p < 0.001). The six month follow-up of tSAH patients complying with the study protocol and treated with intravenous nimodipine, 2 mg per hour for 7 days, showed a statistically significant reduction of unfavourable outcome from 66% to 51% (p < 0.05), compared to placebo treated patients.
在一项欧洲尼莫地平治疗重度颅脑损伤的多中心试验中,819例患者中有268例被纳入分析,这些患者受伤后的首次CT扫描显示有蛛网膜下腔出血迹象。该研究证明了创伤性蛛网膜下腔出血(tSAH)本身作为一种预后因素的重要性。tSAH患者的预后明显比首次CT未显示蛛网膜下腔出血(noSAH)的患者差。60%的tSAH患者预后不良(死亡、持续性植物状态、严重残疾),而noSAH患者为30%(p<0.001)。死亡率差异为42%对14%(p<0.001)。对符合研究方案并接受静脉注射尼莫地平(每小时2毫克,共7天)治疗的tSAH患者进行的六个月随访显示,与接受安慰剂治疗的患者相比,不良预后从66%显著降低至51%(p<0.05)。